×
About 11,306 results

ALLMedicine™ Thrombocytopenia Center

Research & Reviews  5,387 results

Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination.
https://doi.org/10.3949/ccjm.88a.ccc078
Cleveland Clinic Journal of Medicine; McCrae KR

May 7th, 2021 - Vaccine-induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the AztraZeneca ChAdOx1 nCoV-19 and the Johnson and Johnson Ad26. COV2.S vaccines. This manuscript provides a brief overview of reported cases, clinical an...

Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C)...
https://doi.org/10.1080/08880018.2021.1917737
Pediatric Hematology and Oncology; Kok EY, Srivaths L et. al.

May 5th, 2021 - Patients with coronavirus disease 2019 (COVID-19) from novel coronavirus (SARS-CoV-2) infection may present with immune thrombocytopenia (ITP). Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 causing s...

"Indium-labelled autologous platelet sequestration studies predict response to splenect...
https://doi.org/10.1111/imj.15344
Internal Medicine Journal; Ratnasingam S, Ma D et. al.

May 4th, 2021 - Splenectomy is an effective intervention in primary immune thrombocytopenia (ITP). Attempts to define pre-clinical predictors of platelet response to splenectomy are inconsistent. Based on international studies defining the likelihood of platelet ...

A Flow cytometric assay to detect platelet activating antibodies in VITT after ChAdOx1 ...
https://doi.org/10.1182/blood.2021012064
Blood Handtke S, Wolff M et. al.

May 4th, 2021 - Vaccination is crucial in combatting the SARS-CoV-2 pandemic. The rare complication of thrombocytopenia and thrombotic complications at unusual sites after ChAdOx1 nCov-19 vaccination is caused by platelet-activating antibodies directed against pl...

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A...
https://doi.org/10.1007/s12325-021-01752-4
Advances in Therapy; Wojciechowski P, Wilson K et. al.

May 2nd, 2021 - A network meta-analysis (NMA) was performed to assess the efficacy and safety of avatrombopag, relative to eltrombopag, romiplostim, and fostamatinib, for patients with chronic immune thrombocytopenia (ITP) not responding adequately to corticoster...

see more →

Guidelines  17 results

American Society of Hematology 2019 guidelines for immune thrombocytopenia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963252
Blood Advances; Neunert C, Terrell DR et. al.

Dec 3rd, 2019 - Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. These evidence-based guidelines of t...

Dova Pharmaceuticals Announces Fda Approval Of Supplemental New Drug Application For Doptelet® (Avatrombopag) For Treatment Of Chronic Immune Thrombocytopenia (ITP)
http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new

Jun 26th, 2019 - Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA) ap...

American Society of Hematology 2018 guidelines for management of venous thromboembolism...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258919
Blood Advances; Cuker A, Arepally GM et. al.

Nov 29th, 2018 - Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. These evidence-based ...

American Society of Hematology 2018 guidelines for management of venous thromboembolism: hep...
http://www.bloodadvances.org/content/2/22/3360
Cuker, A.

Nov 26th, 2018 - Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism.

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278058
Chest Linkins LA, Dans AL et. al.

Feb 14th, 2012 - Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that can lead to devastating thromboembolic complications, including pulmonary embolism, ischemic limb necrosis necessitating limb amputation, acute myocardial in...

see more →

Drugs  125 results see all →

Clinicaltrials.gov  5,593 results

Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination.
https://doi.org/10.3949/ccjm.88a.ccc078
Cleveland Clinic Journal of Medicine; McCrae KR

May 7th, 2021 - Vaccine-induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the AztraZeneca ChAdOx1 nCoV-19 and the Johnson and Johnson Ad26. COV2.S vaccines. This manuscript provides a brief overview of reported cases, clinical an...

Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C)...
https://doi.org/10.1080/08880018.2021.1917737
Pediatric Hematology and Oncology; Kok EY, Srivaths L et. al.

May 5th, 2021 - Patients with coronavirus disease 2019 (COVID-19) from novel coronavirus (SARS-CoV-2) infection may present with immune thrombocytopenia (ITP). Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 causing s...

"Indium-labelled autologous platelet sequestration studies predict response to splenect...
https://doi.org/10.1111/imj.15344
Internal Medicine Journal; Ratnasingam S, Ma D et. al.

May 4th, 2021 - Splenectomy is an effective intervention in primary immune thrombocytopenia (ITP). Attempts to define pre-clinical predictors of platelet response to splenectomy are inconsistent. Based on international studies defining the likelihood of platelet ...

A Flow cytometric assay to detect platelet activating antibodies in VITT after ChAdOx1 ...
https://doi.org/10.1182/blood.2021012064
Blood Handtke S, Wolff M et. al.

May 4th, 2021 - Vaccination is crucial in combatting the SARS-CoV-2 pandemic. The rare complication of thrombocytopenia and thrombotic complications at unusual sites after ChAdOx1 nCov-19 vaccination is caused by platelet-activating antibodies directed against pl...

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A...
https://doi.org/10.1007/s12325-021-01752-4
Advances in Therapy; Wojciechowski P, Wilson K et. al.

May 2nd, 2021 - A network meta-analysis (NMA) was performed to assess the efficacy and safety of avatrombopag, relative to eltrombopag, romiplostim, and fostamatinib, for patients with chronic immune thrombocytopenia (ITP) not responding adequately to corticoster...

see more →

News  163 results

Immune Response May Explain Rare Clots After AstraZeneca Vaccine
https://www.medscape.com/viewarticle/948389

Mar 30th, 2021 - (Reuters) - Researchers may have found an explanation for the rare but serious blood clots reported among some people who received AstraZeneca's COVID-19 vaccine. They believe the phenomenon is similar to heparin-induced thrombocytopenia (HIT), in...

Mycophenolate Shows Promise in Immune Thrombocytopenia
https://www.medscape.com/viewarticle/942584

Dec 13th, 2020 - A drug currently used to prevent rejection in patients who receive solid organ transplants could have a use in the treatment of a completely different patient population ― those with immune thrombocytopenia (ITP). The drug is mycophenolate mofetil...

Mycophenolate a Potential First-line Therapy for ITP
https://www.medscape.com/viewarticle/942374

Dec 9th, 2020 - Treatment-naïve immune thrombocytopenia (ITP) patients could more than halve their risk of treatment failure with mycophenolate alongside a course of corticosteroids compared with corticosteroids alone, conclude UK researchers in the first randomi...

Falling Splenectomy Rates in ITP Raise Questions Over Role
https://www.medscape.com/viewarticle/929773

May 10th, 2020 - Patients with immune thrombocytopenia (ITP) are undergoing fewer and fewer splenectomies later and later in the disease course, which is resulting in lower gains from the procedure, say UK researchers, who question its ongoing role. The research w...

BET inhibitor exhibits activity in myelofibrosis
https://www.mdedge.com/hematology-oncology/article/215490/cythemias/bet-inhibitor-exhibits-activity-myelofibrosis/page/0/1?channel=50517

Jan 14th, 2020 - Safety “CPI-0610 monotherapy or as an add-on to [ruxolitinib] was generally well tolerated,” Dr. Mascarenhas said.

see more →

Patient Education  21 results see all →